No Data
No Data
Medical Technology Firms Face Price Target Revisions From Morgan Stanley
Morgan Stanley Adjusts Price Target on RxSight to $20 From $42, Maintains Overweight Rating
RxSight, Inc. (NASDAQ:RXST) Just Reported Earnings, And Analysts Cut Their Target Price
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
Express News | Rxsight Inc : BofA Global Research Cuts Price Objective to $18 From $22
RxSight's Hold Rating: Balancing Strong Gross Margins and Macroeconomic Pressures With Promising Business Models